skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Costos de la Esclerosis Múltiple en Colombia

Romero, Martin, MD, MSc ; Arango, Carlos, MD, MSc ; Alvis, Nelson, MD, MSc, PhD ; Suarez, Juan Camilo, MD ; Duque, Aristides, MD, MEsp (Neurol)

Value in health, 2011-07, Vol.14 (5), p.S48-S50 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    Costos de la Esclerosis Múltiple en Colombia
  • Autor: Romero, Martin, MD, MSc ; Arango, Carlos, MD, MSc ; Alvis, Nelson, MD, MSc, PhD ; Suarez, Juan Camilo, MD ; Duque, Aristides, MD, MEsp (Neurol)
  • Assuntos: Internal Medicine
  • É parte de: Value in health, 2011-07, Vol.14 (5), p.S48-S50
  • Descrição: Abstract Objective To estimate, according to the states of disease (remission or relapse) and her level of progression (EDSS), the cost of treatment of Multiple Sclerosis (MS) in Colombia. Methods From the perspective of the third payer, a cost study of MS was performed using two-way estimation techniques: a) “Top down” to estimate the costs during relapses from clinical registers of 304 patients; b) “bottom-up” to estimate the cost in remission from a questionnaire (Kobelt 2006) applied to 137 patients, located in different regions of Colombia. Results The mean of patient's age was 43,7 years and 73% of those were women. The mean annual cost per patient varied according to the disease phase, finding the highest value in Phase II (EDSS 3 – 5,5) with $ 50.581.216 COP (US$ 25.713) and the lowest one in Phase IV (EDSS 8 - 9,5) with $20.738.845 COP (US$ 10.543). The cost of Disease Modifier Drugs (DMD) represented 91.5% from the medial total annual cost of 1,2 and 3 phases. The participation of DMD was 58%.in the 4 phase. Indirect costs are minimal participation in all phases, except for 4 where increases at the expense of reduced consumption of DMD. Costs associated with the period of relapses of MS are low against the total cost, with an average cost of $ 2,433,182 COP ($ 1.237USD). Discussion MS in Colombia is a disease with a behavioral pathology ”high cost ” to the social security system (SGSSS), generated mainly at the expense of their direct costs, which, even without including relapses, an aggregate amount of more than 75 times the annual premium cost of health insurance for Colombia ($ 430,488 COP) in the year under review (2008)
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.